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Abstract
Background: Pelvic symptoms are distressing symptoms experienced by patients with Friedreich’s Ataxia (FRDA).
The aim of this study was to describe the prevalence of lower urinary tract symptoms (LUTS), bowel and sexual
symptoms in FRDA.
Methods: Questionnaire scores measuring LUTS, bowel and sexual symptoms were analysed with descriptive statistics
as a cohort and as subgroups (Early/Late-onset and Early/Late-stage FRDA) They were also correlated with validated
measures of disease severity including those of ataxia severity, non-ataxic symptoms and activities of daily living.
Results: 80% (n = 46/56) of patients reported LUTS, 64% (n = 38/59) reported bowel symptoms and 83% (n = 30/36)
reported sexual symptoms. Urinary and bowel or sexual symptoms were significantly likely to co-exist among patients.
Late-onset FRDA patients were also more likely to report LUTS than early-onset ones. Patients with a longer disease
duration reported higher LUTS scores and poorer quality of life scores related to urinary symptoms.
Conclusions: A high proportion of FRDA have symptoms suggestive of LUTS, bowel and sexual dysfunction. This is
more marked with greater disease duration and later disease onset. These symptoms need to be addressed by
clinicians as they can have a detrimental effect on patients.
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Background
Friedreich’s Ataxia (FRDA) is the most common hereditary
ataxia with an estimated prevalence in Western European
populations varying from 1:125,000 to 1:20,000 [1, 2]. It is
an autosomal recessive neurodegenerative disorder involv-
ing defects of the frataxin (FXN) gene on chromosome 9,
which encodes the mitochondrial protein, frataxin [3].
This results in a deficiency of mitochondrial Complex I
activity and an increase of lipid peroxidation causing cell
death [4]. Its clinical phenotype includes neurological
features such as impaired co-ordination, dysarthria, weak-
ness, ocular ataxia, spasticity, sensory loss and hearing
impairment, and non-neurological features such as cardio-
myopathy, diabetes mellitus, kyphoscoliosis and foot de-
formities [5–7]. Atypical and much rarer phenotypes
have also been described [8]. Less commonly studied
features of FRDA include cognitive impairment and
lower urinary tract symptoms (LUTS) [9].
Previous cohorts of FRDA patients have noted com-
plaints of sphincter disturbance or urinary incontinence
but this has not been clarified further [5, 10–13]. Only
one large study of 258 FRDA patients showed that 82%
of patients reported LUTS and 22% related these symp-
toms to poorer quality of life [14]. Smaller case-series
have evaluated LUT function in a select group of pa-
tients but this has not been extended to larger groups.
The aim of this study was to describe LUTS, bowel and
sexual symptoms in FRDA patients and to describe this
in relation to other established clinical and genetic fea-
tures. A further aim was to look at the differences between
early-onset and late-onset FRDA (more than 25 years of
age) and early and late-stage FRDA (more than 15 years’
disease duration). Additionally, the co-existence of urin-
ary, bowel and sexual symptoms and associations with
clinical characteristics was studied.
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Methods
Patient information and data collection
Patients (>16 years of age) with FRDA were recruited for
this study. All questionnaires were administered at the
time of an annual patient clinic appointment or returned
at a later date via post. Informed consent was obtained
from all patients and approval was gained from the local
Research Ethics Committee as a service evaluation.
All patients had a confirmed diagnosis of FRDA by
genetic analysis with homozygous expansions of intron 1
of the FXN gene. GAA repeat sizes were determined by
polymerase chain reaction (PCR) by the Laboratoire de
Neurologie Expérimentale of the Université Libre de
Bruxelles (ULB) in Brussels, Belgium and the GAA re-
peat size of the smaller allele (GAA1) was used for
further analysis.
Questionnaires
The Scale for the Assessment and Rating of Ataxia
(SARA) has been validated for both spinocerebellar
ataxia and FRDA and has been used as a primary out-
come measure in some studies [15, 16]. This quantifies
ataxia symptoms with higher scores reflecting severe
ataxia. The maximum score is 40. The Inventory of
Non-Ataxic Symptoms (INAS) is a checklist of non-ataxic
symptoms such as other motor and sensory symptoms,
ocular signs and cognitive impairment [17]. This also in-
cludes a point for urinary dysfunction which was excluded
from the questionnaire for our study. The maximum score
is 29. The Activities of Daily Living (ADL) questionnaire
was used as a marker of disability as it contains questions
pertaining to daily function [18]. It is a section of the
Friedreich Ataxia Rating Scale (FARS) [19]. The maximum
score is 32. Patients did not complete the other sections of
the FARS as they had already completed the question-
naires assessing disease severity as part of the European
Friedreich’s Ataxia Consortium for Translational Studies
(EFACTS) protocol [20].
The Urinary Symptom Profile (USP) was used to char-
acterise urinary symptoms [21]. This is divided into 3
sections – Stress Incontinence (SI), Overactive Bladder
(OAB) and Low Stream (LS) symptoms. OAB and LS
scores were used for further analysis as these have been
considered neurogenic symptoms. The maximum score
is 21 for OAB and 7 for LS. We also included the 8-item
SF-Qualiveen questionnaire which has been validated for
assessing the quality of life in neurological patients with
urinary symptoms [22]. This questionnaire focusses on 4
aspects of patients’ lives with respect to their urinary
symptoms. This includes how frequently patients are af-
fected and/or limited by their urinary symptoms and ex-
plores their fears and feelings with respect to this. The
total maximum score is 4. The Neurogenic Bowel Dys-
function (NBD) score was also used to assess bowel
symptoms in these patients [23]. This is a questionnaire
comprising 10 questions regarding elements of bowel
dysfunction: the instrument has been correlated with
patient quality of life, specifically in patients with neuro-
logical disease. The categories in order of severity are:
0–6 ‘very minor’, 7–9 ‘minor’, 10–13 ‘moderate’ and >13
‘severe’. The maximum score is 30. The Arizona Sexual
Experience Scale (ASEX) was used to assess sexual
symptoms in our patients [24]. This is a 5-item rating
scale that has been validated and is widely used in the
field of psychiatry. A patient is said to have sexual dys-
function if they score 19, a score of five in any one ques-
tion or three fours in separate questions. The sexual
domains consist of sexual drive, arousal, penile erection/
vaginal lubrication, orgasm and enjoyment.
Statistical analysis
Descriptive analysis was conducted to calculate the mean,
range (R) and standard deviation (SD) of the patient
demographics, clinical characteristics and scores from the
questionnaires evaluating their pelvic symptoms. This in-
cluded a test of normality using the Shapiro-Wilks test.
For this study, patients were also divided into those with a
longer disease duration (>15 years) and those with shorter
disease duration and into those with disease onset later in
life (after 25 years of age) and those with young-onset
FRDA. Group-level comparisons of mean values was per-
formed using t-tests. To study the co-existence of urinary,
bowel and sexual symptoms, an analysis of proportions of
those patients that scored any points on the OAB, LS and
NBD questionnaires and/or had sexual dysfunction on the
ASEX was conducted using McNemar’s chi square test.
This analyses differences in paired proportions from the
same sample. Group-level analysis for patients that scored
on any questionnaire and those that did not were
performed using the Mann-Whitney U-test for non-
parametric data and t-tests for parametric data. Pearson’s
coefficients are shown for any correlations. This was per-
formed to calculate the strength of association between
variables related to disease severity and questionnaire
scores for pelvic symptoms.
All statistical tests were conducted using IBM SPSS
Statistics for Windows, version 21.0 (IBM Corp., Armonk,
NY, 2012). A p-value of less than 0.05 was required for
significance with Bonferroni correction.
Results
Patient Characteristics & Measures of disease severity
Fifty-nine patients (31 male) were recruited with a mean
age of 35 years (R = 17–70, SD = 13). The mean age of
onset of ataxia was 17 years (n = 53, R = 1–56, SD = 12)
and mean duration of ataxia was 19 years (n = 50,
R = 4–46, SD = 9). The mean size of the GAA (allele 1)
repeats in the FXN gene was 642 repeats (n = 50,
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R = 67–1200, SD = 304) and for allele 2 was 944
(n = 50, R = 500–1234, SD = 218). Twenty-four patients
were wheelchair bound. The signs elicited by our pa-
tients are shown in Table 1. SARA scores for the FRDA
patients had a mean of 23 (R = 4.5–40, SD = 10), ADL
scores had a mean of 16 (R = 1–32, SD = 9) and the
INAS had a mean of 5 (R = 1–9, SD = 1.6). Results of
these measures are shown in Table 2.
LUTS, bowel and sexual symptoms scores
Forty-six patients (80%, n = 46/56) scored at least 1
point on the OAB section of the USP questionnaire and
17 (30%, n = 17/56) had LS symptoms. A breakdown of
the OAB symptom scores is shown in Table 3. The OAB
section had a mean score of 4.3 (R = 0–12, SD = 4). All
patients scored at least 1 point on the SF-Qualiveen
questionnaire (38 patients (68%, n = 56) completed the
questionnaire). Scores had a mean of 1.2 (R = 0.1–3.6,
SD = 0.9). The scores can be divided into the following
categories with the percentage who reported symptoms
in parenthesis: bother of limitations (73%), fears (89%),
associated feelings (73%) and frequency of limitations
(89%). Seven patients were taking anti-muscarinic medi-
cation for their urinary symptoms. One had had surgery
for their symptoms, two required the use of a urinary
catheter and one wore pads. These patients were ex-
cluded from some analyses as they did not complete
most sections of the OAB and LS. Urodynamic studies
in one patient showed detrusor overactivity and the max-
imum cystometric capacity in this patient was 350 mls.
Another had urodynamic studies showing detrusor over-
activity. Two patients had a mean residual volume of 30
mls (R = 20–40).
Thirty-seven patients (64%, n = 38/59) scored at least
a point on the NBD questionnaire (Table 4). These
patients reported the following more frequently: reduced
frequency (86%), associated medication use (24%) and
faecal incontinence (16%). The mean NBD score was 3
(R = 0–26, SD = 5): 6 (10%) patients scored above 10
(indicative of moderate to severe bowel dysfunction).
There was no difference in the means of ambulatory and
wheelchair-bound patients in a post-hoc analysis with in-
dependent t-tests. ASEX scores had a mean of 10
(n = 36, R = 0–30, SD = 7) (Table 5). According to the
scoring criteria described above, 25% (n = 9, 5 females)
had sexual dysfunction. One female and 1 male partici-
pant scored above 19. Seventeen out of the 36 patients
that completed the questionnaire were sexually active. A
summary of the total scores of the OAB, SF-Qual, NBD
and ASEX questionnaires is given in Table 2.
Table 1 Signs and Symptoms of FRDA patients in our Cohort
(n = 59)




Reduced Vibration Sense 88
Lower-limb Areflexia 78
Lower-limb Muscle Weakness 76
Swallowing Difficulties 67
Extensor Plantar Reflexes 56
Lower-limb Wasting 46
Horizontal Nystagmus 40
Saccadic Pursuit Eye Movements 8
Patellar Reflexes Present 6
FRDA – Friedreich’s Ataxia
Table 2 FRDA Patient Scores on Questionnaires
Questionnaire n = 59 Mean Score sd Range
Age of Onset 16.8 years 12.3 1–56
Duration of Ataxia 18.6 years 9 4–46
SARA 23 10 4.5–40
ADL 16 9 1–32
INAS 5 1.6 1–9
Questionnaire n* Mean Score sd Range
OAB 56 4.3 4 0–12
SF-Qual 38 1.2 0.9 0.1–3.6
NBD 59 3 5 0–26
ASEX 36 10 7 0–36
FRDA – Friedreich’s Ataxia; SARA – Scale for the Assessment and Rating of
Ataxia; ADL – Activities of Daily Living scale; OAB – Overactive Bladder score
(subsection of Urinary Symptom Profile); SF-Qual – SF-Qualiveen quality of life
score; NBD – Neurogenic Bowel Disease scale; ASEX – Arizona Sexual Experience
scale. Higher scores indicate severe symptoms in each questionnaire
*The total number of patients is calculated based on those who replied to the
specific questions in the questionnaires and were included in the final analysis
Table 3 Results from USP for OAB and LS symptoms
USP Section N = 56* Percentage (%)






Nocturnal Incontinence 7 13
LS Score 17 30
Voiding 4 7
Urinary Flow 7 13
Stream 17 30
USP- Urinary Symptoms Profile, OAB – Overactive Bladder, LS – Low Stream
*2 patients did not complete all sections of the questionnaire as they
used a urinary catheter and 1 patient did not complete all sections of the
questionnaire as she wore pads
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Co-existing pelvic symptoms and severity of FRDA
Out of 45 patients who reported OAB, 33 (73%) also
scored on the NBD questionnaire, reporting symptoms
suggestive of bowel dysfunction (p = 0.12, McNemar’s
chi-squared test) and those who had LS symptoms were
significantly likely to have scored on the NBD (n = 14/
17, p = 0.001, McNemar’s chi-squared test). These pa-
tients were likely to have higher scores in the NBD ques-
tionnaire (U = 143.5, p = 0.005) and ADLs (U = 162.0,
p = 0.04) but not on the SARA and INAS. Patients with
OAB were also significantly more likely to have scores
on the ASEX indicating sexual dysfunction (n = 7/19,
p < 0.001, McNemar’s chi-squared test). There were no
patients without LUTS who had scores suggestive of
sexual dysfunction (defined by considering all criteria) in
our cohort. Patients with bowel symptoms were also more
likely to have sexual dysfunction than not (n = 5/17,
p = 0.021, McNemar’s chi-squared test).
Relationship of duration of ataxia, measures of Disease
Severity & Symptom Scores
The number of GAA repeats of the smaller allele was
correlated with the onset of ataxia (p < 0.001, R(53) =
−0.501) and SARA scores (p = 0.004, R(50) = 0.404) only.
Duration of ataxia correlated significantly with increased
scores on the ADLs questionnaire (p = 0.001, R(50) = 0.440)
and with SARA scores (p = 0.006, R(50) = 0.383). This
also showed significant correlations with OAB (p = 0.027,
R(47) = 0.322) and LS scores (p = 0.014, R(48) = 0.353). A
trend was observed with age of ataxia onset and OAB
(p = 0.240, R(49) = 0.171) and LS (p = 0.108,
R(50) = 0.230) scores.
Patients with a late-stage FRDA (defined as disease
duration >15 years) had significantly higher scores of
OAB by 2.5 points (t(45) = 2.24, p = 0.03), LS by 1 point
(U = 180.0, p = 0.010), SF-Qualiveen by 0.8 points
(U = 65.0, p = 0.009), SARA by 6.7 points (t(48) = 2.61,
p = 0.012), ADLs by 6 points (t(48) = 2.74, p = 0.009)
and INAS by 1 point (t(47) = 2.24, p = 0.03). Late-onset
FRDA (defined as onset >25 years of age) patients had
significantly higher scores in the OAB (t(47) = 2.53,
p = 0.015) and LS scores by 1.4 points (t(48) = 3.07,
p = 0.004).
Discussion
To our knowledge, this is the first study to describe
LUTS, bowel and sexual symptoms in a cohort of FRDA
patients. Our findings show that a large proportion of
patients report LUTS (80%) and bowel (64%) symptoms.
25% of patients are classified as having sexual dysfunction
according to ASEX criteria. In the literature, other studies
have reported the prevalence of ‘sphincter disturbance’
and ‘urinary incontinence’. This ranges from 7% to 41%
but has not been explored further [5, 10–12, 25]. At a
group level, we also showed significant differences in
LUTS scores between early and late-onset FRDA patients.
The latter had higher LUTS scores. The late-stage FRDA
patients also had higher scores in this domain alongside
higher scores on the SF-Qualiveen, indicating poorer
urinary quality of life. This may be due to higher levels
of spasticity in these patients or it may be physiological
at an older age [20].
LUTS were commonly reported by our cohort of pa-
tients, however, only 24% of patients were on any form
of treatment at presentation. The most commonly used
agents for this were anti-muscarinic medications. The
urodynamic findings were consistent with larger case-series
that have shown detrusor overactivity as the predominant
finding, however, only 2 patients had these tests [26, 27].
Other findings on urodynamic studies have included de-
trusor underactivity, detrusor acontractility and detrusor-
sphincter dyssynergia [14]. This would account for the
urinary disturbances reported by our patients as there were
high scores in OAB indicating detrusor overactivity and LS
indicating possible detrusor-sphincter dyssynergia due to
pyramidal tract involvement or peripheral neuropathy.
The mechanisms for urinary disturbances in FRDA are
multi-factorial, as disease affects the pyramidal tracts,
posterior cord, spinocerebellar pathways, spinal ganglia,
cerebellum and peripheral nerves [26, 28]. Lesions of the
supra-pontine or spinal pathways that regulate LUT
function affect the storage phase, causing reduced blad-
der capacity and detrusor overactivity. Spasticity has
been well described in FRDA patients, especially in the
later stages of the disease [20]. However, our findings
did not correlate significantly with spasticity scores after
Table 4 A Breakdown of Scores from the NBD Questionnaire
NBD Score N = 59 Percentage (%)
NBD Combined 37 64
Very Minor Dysfunction 28 48
Minor Dysfunction 3 5
Moderate Dysfunction 3 5
Severe Dysfunction 3 5
NBD- Neurogenic Bowel Dysfunction Score
Table 5 ASEX Questionnaire sub-sections
ASEX Score N = 36* Percentage (%)
Sexually Active 17 47
Sexual Dysfunction 9 25
>19 overall 1 3
3 scores of 4 6 17
5 in 1 domain 2 6
ASEX- Arizona Sexual Experience Scale
*23 out of 59 patients did not wish to complete the questionnaire
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correction for multiple comparisons. This is possibly
due to the severe peripheral neuropathy that ‘masks’
corticospinal tract involvement. Additionally, although
patients with peripheral neuropathy report sensation of
bladder fullness, inability to initiate micturition voluntarily
and bladder distension, a subset experience detrusor over-
activity, which could be a result of bladder decentralisa-
tion due to preserved peripherally sited post-ganglionic
neurons [29].
Neuropathological studies of FRDA have shown degener-
ation of the dentate nuclei, dorsal root ganglia, peripheral
nerves and corticospinal tracts [30]. Neurophysiological
studies reveal that formerly quiescent C-fibres become the
major afferent from the bladder, after spinal cord injury,
which drives detrusor overactivity via activation of this
aberrant spinal reflex [31]. Spinal pathways connecting
the pontine micturition centre to the sacral cord coord-
inate reciprocal activity of the detrusor and sphincter
muscles. Interruption of these pathways results in
detrusor-sphincter dyssynergia causing incomplete blad-
der emptying with high detrusor pressures. Sacral and
infra-sacral lesions lead to poorly sustained detrusor con-
tractions and/or non-relaxing sphincters and damage to
parasympathetic innervation of the detrusor and bowel,
which is responsible for accelerating bowel transit, can
lead to urinary incontinence and constipation respectively
[32]. Similarly, degeneration of the somatic and parasym-
pathetic nervous system may give rise to symptoms sug-
gestive of sexual dysfunction [33].
More than half of our patients (64%) reported symp-
toms suggestive of neurogenic bowel dysfunction albeit
the mean score indicated ‘very minor’ bowel dysfunction.
Nevertheless, there was a significant minority of patients
with moderate or severe bowel symptomatology, suggest-
ing that for some, bowel dysfunction can be an extremely
intrusive aspect of FRDA. We noted that 25% of our
FRDA patients who completed the ASEX questionnaire
had sexual dysfunction. This was not confined to any
domain as patients reported high scores diagnostic of
sexual dysfunction uniformly for all questions. In addition,
we did not find any significant relationships with rating
scales of FRDA severity and this may be due to the com-
plex behavioural and neurophysiological nature of sexual
function.
Patients with urinary or bowel symptoms were signifi-
cantly more likely to have sexual dysfunction that those
without. This highlights the importance for screening
for symptoms in all three domains when patients are
encountered by clinicians. When urinary symptoms are
encountered, for example, one can manage this with
medication such as antimuscarinic agents, intravesical
Botox injections, percutaneous tibial nerve stimulation
and/or referral to specialist urology services. Moreover,
patients were significantly affected in terms of their
quality of life for urinary symptoms and we would an-
ticipate similar ratings in quality of life measures for
bowel and sexual symptoms. Studies in the future need
to address these issues. Some limitations of our study
include the slightly older cohort of patients compared
to other large studies and the lack of neuropathological
data. Urodynamic data on all patients would also be
helpful to characterise any differences in sub-groups.
Conclusions
LUTS, bowel and sexual symptoms are under-recognised,
under-discussed and undertreated. Clarifying whether
these symptoms are related to pelvic dysfunction will also
allow clinicians to target therapies to manage these highly
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